Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
Authors:
- 21 June 2019
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 79 (11) , 1199-1215
Abstract
Standard treatment of cutaneous lupus erythematosus (CLE) includes preventive measures such as smoking cessation and photoprotection associated with topical therapies and antimalarial agents, which are recommended as first-line systemic treatment. In more severe disease, alternative therapeutic options include immunosuppressive and immunomodulatory drugs. Recently, the development of specific tools to assess CLE activity and the publication of European CLE guidelines have improved the management of CLE. Moreover, several biologic agents are currently being studied specifically in CLE or in systemic lupus erythematosus with assessment of skin involvement and may be promising therapies. However, improvement of the management of CLE remains a major unmet need. In this review, we summarize current concepts in the management of CLE as well as future approaches for more targeted treatments.Keywords
This publication has 143 references indexed in Scilit:
- Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosusArthritis Research & Therapy, 2012
- Taming lupus—a new understanding of pathogenesis is leading to clinical advancesNature Medicine, 2012
- Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flareJournal of the American Academy of Dermatology, 2012
- Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication StudyThe American Journal of Human Genetics, 2012
- Impact of Smoking in Cutaneous Lupus ErythematosusArchives of Dermatology, 2012
- Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with Systemic Lupus ErythematosusPLOS Genetics, 2011
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology & Oncology, 2009
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2007